Journal
NEUROCHEMICAL RESEARCH
Volume 47, Issue 2, Pages 205-217Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11064-021-03448-1
Keywords
Apelin-13; AD; Amyloid beta; Neuroprotection
Categories
Funding
- National Natural Science Foundation of China [82060250]
- Guangxi Science and Technology Plan Project [AD20238035]
- Open Project of Guangxi Key Laboratory of Brain and Cognitive Neuroscience [GKLBCN-20190105-02]
- Guangxi Zhuang Autonomous Region Students' Innovation and Entrepreneurship Training Program of China [202010601050]
Ask authors/readers for more resources
Alzheimer's disease is the most common type of dementia, and the number of cases is expected to increase. Apelin-13, a neuroprotective peptide, regulates cell activities to prevent the development of AD.
Alzheimer's disease (AD) is the most common type of dementia. Currently, more than 50 million people live with dementia worldwide, and this number is expected to increase. Some of the typical pathological changes of AD include amyloid plaque, hyperphosphorylation of tau protein, secretion of inflammatory mediators, and neuronal apoptosis. Apelin is a neuroprotective peptide that is widely expressed in the body. Among members of apelin family, apelin-13 is the most abundant with a high neuroprotective function. Apelin-13/angiotensin domain type 1 receptor-associated proteins (APJ) system regulates several physiological and pathophysiological cell activities, such as apoptosis, autophagy, synaptic plasticity, and neuroinflammation. It has also been shown to prevent AD development. This article reviews the research progress on the relationship between apelin-13 and AD to provide new ideas for prevention and treatment of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available